Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class

IRVING, Texas, Nov. 21, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the selection of 15 physician-scientists to participate in its 2025/2026 Caris Precision Oncology Alliance (Caris POA) Fellows Forum. This competitive two-year program provides early-career oncologists with hands-on training, mentorship and access to real-world molecular data, empowering them to develop and test clinically meaningful precision medicine hypotheses.

To be considered for the program, applicants must be physician-scientists in their first or second year of oncology fellowship at one of Caris' POA institutions. Caris POA fellows were chosen through a competitive review process evaluating academic achievements and research track record, interest and potential in molecular oncology. Those accepted into the Fellows Forum will experience:

• Direct mentorship from Caris experts and leading faculty at Caris POA institutions
• Access to Caris' CODEai database (catalog of molecular data with cancer treatment information and clinical outcomes data for more than 484,000 patients, covering greater than one million data points per patient)
• Collaborative research projects spanning over 97 cancer institutions and research consortia
• Structured educational modules, virtual webinars and lab tours

"Investing in the next generation of oncology leaders allows us to advance research while also accelerating discoveries that will change how we diagnose and treat cancer," said James Hamrick, MD, MPH, Chairman of the Caris Precision Oncology Alliance. "This year's class represents the future of precision oncology and we're excited to support their journey."

Fellows dedicate time monthly alongside their ongoing clinical or academic duties, participating in data analysis, seminars and mentorship sessions that sharpen their expertise in molecular oncology.

Fellows Forum members will convene periodically to foster community and exchange insights, including a guided tour of Caris' Blood and Tissue Labs in Phoenix, the Caris POA Summit at the ASCO Annual Meeting and via monthly virtual workshops for research updates and skill-building. These gatherings reinforce a shared theme to translate molecular insights into improved patient outcomes worldwide.

"As Chair of the Caris Precision Oncology Alliance Fellows Forum, I'm honored to further the POA's commitment by investing in the future of precision oncology," said Emil Lou, MD, PhD, FACP, University of Minnesota, Division of Hematology, Oncology and Transplantation. "Mentoring the next generation of leaders through collaboration and empowering fellows to transform molecular insights into discoveries that will improve patient care for years to come."

Caris Precision Oncology Alliance Fellows Forum 2025-2026 members:

• Akram Alkrekshi, MD, MedStar Georgetown University Hospital
• Stefan Barisic, MD, Hematology & Medical Oncology Fellow, Duke University Hospital
• Paul Stendahl Dy, MD, MBA, University of Maryland Greenebaum Comprehensive Cancer Center
• Bharath Ganesh, MD, FACP, PGY-4 Hematology/Oncology Fellow, Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
• Kevin C. Graf, MD, Medical University of South Carolina
• Christopher Grant, MD, PGY-5, Division of Hematology-Oncology, UC San Diego School of Medicine
• Jennifer Hwang, MD, Hematology & Medical Oncology Fellow, The Ohio State University
• Anand Kornepati, MD, PhD, Hematology & Medical Oncology Fellow, Duke University Hospital
• Samantha Leite MD, Gynecologic Oncology Fellow, National Capital Consortium (Walter Reed National Military Medical Center/Inova Health System)
• Dan Morgenstern Kaplan, MD, MSc, First Year Hematology/Oncology Fellow, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine
• Janina Pearce, MD, PhD, Women and Infants Hospital/Brown University 
• Natalie Reed, DO, PGY-4, Hematology Oncology fellow, Atrium Health Levine Cancer
• Ryan Michael Reyes, MD, PhD, Washington University School of Medicine in St. Louis
• Kelsey Roof, MD, Emory University School of Medicine
• Grace Sun, MD, Clinical Fellow in Hematology-Oncology, UC Davis Comprehensive Cancer Center

About Caris Life Sciences 
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions. 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Quarterly Report on Form 10-Q filed on or about November 5, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:
Corporate Communications
[email protected]
214.294.5606

SOURCE Caris Life Sciences